Key terms
About MTNB
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MTNB news
Apr 05
7:12am ET
Matinas BioPharma’s Multi-Million Share Sale and Lock-Up Deal
Apr 03
8:39am ET
Matinas BioPharma prices 33.33M shares at 30c in registered direct offering
Apr 02
10:35am ET
Matinas BioPharma (MTNB) Gets a Buy from Maxim Group
Mar 28
9:13am ET
Matinas BioPharma Updates Presentation for Investor Outreach
Mar 25
8:31am ET
Matinas announces in vivo safety data with oral LNC-doxetaxel formulation
Mar 25
8:22am ET
Matinas BioPharma’s LNC Technology Promises Safer Chemotherapy
Mar 22
9:33am ET
Matinas BioPharma’s MAT2203 Shows Promising Clinical Results
Mar 22
6:31am ET
Matinas BioPharma regains compliance with NYSE American
Feb 26
8:22am ET
Matinas BioPharma’s MAT2203 Shows Renal Improvement and Infection Recovery
Feb 26
8:09am ET
Matinas BioPharma provides update from Compassionate/EUA Program with MAT2203
Feb 20
7:52am ET
Matinas BioPharma Advances MAT2203 in Phase 3 Global Trial
Feb 20
7:35am ET
Matinas BioPharma reaches agreement with FDA for Phase 3 trial of MAT2203
Jan 07
5:41am ET
BTIG Sticks to Their Buy Rating for Matinas BioPharma (MTNB)
No recent press releases are available for MTNB
MTNB Financials
Key terms
Ad Feedback
MTNB Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MTNB Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range